Key Takeaways
- The first Innovative Cell Therapy and Personalized Medicine Center in the Baltic States has opened in Vilnius, backed by a €61 million investment from Northway Group.
- This facility enhances Northway Biotech’s capabilities in gene therapy, cell-based technologies, and personalized medicine.
- Founded by Prof. Vladas Algirdas Bumelis, the center celebrates the 15th anniversary of its parent company, which has developed expertise in advanced therapies over the years.
New Cell Therapy Center Launches in Vilnius
Northway Biotech has inaugurated the first specialized Innovative Cell Therapy and Personalized Medicine Center in the Baltic States, located in Vilnius, Lithuania. This opening represents a significant expansion of Northway’s contract development and manufacturing organization (CDMO) capabilities in advanced therapies, supported by a €61 million investment.
The new 3,500 square meter facility is part of the broader BIO CITY III initiative and will significantly boost Northway Biotech’s existing CDMO platform. It focuses on mammalian and microbial biologics, gene therapy, and cell-based technologies, allowing for increased development and Current Good Manufacturing Practice (cGMP) manufacturing capacity for advanced, personalized therapies. The facility is designed to assist biotechnology firms, pharmaceutical companies, university hospitals, and research institutions, and is already commencing operations with several customers onboard.
Equipped with specialized infrastructure and technologies, the center will facilitate the cGMP manufacturing and development of autologous and allogeneic cell-based therapies, as well as personalized therapeutic vaccines and regenerative medicine applications. Its segregated manufacturing infrastructure allows for multiple cell-based products and processes to be managed simultaneously while adhering to strict standards regarding product identity, quality, traceability, and contamination control.
This milestone also commemorates the 15th anniversary of the Stem Cell Research Center, which operates under the Northway Biotech brand. Founded in 2011 by Prof. Vladas Algirdas Bumelis, the center has dedicated years to building expertise in cGMP environments and advancing in stem cell research and cell-based technologies.
Reflecting on the journey, Bumelis emphasized the center’s transformation from ambition to reality: “Fifteen years ago, we did not have a €61 million center – we had people and ambition. Over the years, we have built practical experience, grown our team, and advanced our cell technology capabilities. Today, we are systematically taking all of this to an entirely new scale. What seemed like the future of medicine 15 years ago is now being created here in Lithuania.”
The content above is a summary. For more details, see the source article.